BTW, FWIW, I didn't say 2011, hard. I said 2011-2012.....2011 would be based on results similar to Gleevec's approval. 2012 is probably more reasonable. Considering Ariad is not going for "front line" but all resitant forms, they likely can get an expedited approval. I highly doubt there is going to be any head-to-head, or placebo study in the pivotal trial they are going to run
Market Data 
Markets
AI
